Oct 23, 2024
Press Release: Aletheia Neuroenergetics Study in Amyotrophic Lateral Sclerosis (ALS) Accepted for Presentation at the NEALS 2024 Annual Meeting
Novel Neuroenergetic Gene Therapy for ALS Resulted in Improved Motor Performance and Prolonged Survival
Aletheia Neuroenergetics is a biotechnology company developing first-in-class neuroenergetics therapies designed to augment and rescue the pathological ATP energy deficits caused by neurodegenerative disease. Pathological neuroenergetic dysfunction is an early event on the path to progressive neurodegeneration and interventions targeted to the augmentation of energetic metabolism would support synaptic function to the detriment of progressive neuropathology.
Over the last few decades of research, impaired bioenergetics (manifest as decreased ATP bioavailability associated with mitochondrial dysfunction) have emerged as a common denominator across the entire clinical spectrum of neurodegenerative disease, including ALS. Motor neurons in particular have exceptionally high metabolic demands imposed by scale. Motor neuron axons may extend up to 1 meter in length, with the maintenance of action potential necessary for function of the neuromuscular junction incurring a disproportionately high requirement for uninterrupted energy supply. Energetic dysfunction is a prominent hallmark of both familial and sporadic forms of ALS, suggesting therapeutic strategies that are able to augment energy metabolism may be applicable to all forms of disease.
Aletheia will present a poster entitled “Gene Therapy Mediated Recompartmentalization of Aspartoacylase Promotes Delayed Onset of Motor Dysfunction and Increases Lifespan in the SOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis” which has been accepted for presentation at the NEALS 2024 Annual meeting, October 21-24. The Annual NEALS meeting is a cornerstone event for NEALS that epitomizes the collaboration and innovation within the ALS research community.
Presentation Details:
Title: Gene Therapy Mediated Recompartmentalization of Aspartoacylase Promotes Delayed Onset of Motor Dysfunction and Increases Lifespan in the SOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis
Presenter: Jeremy Francis, Ph.D.
Poster: 183
Poster Session Date: Wednesday, October 23, 2024
About Aletheia Neuroenergetics:
Aletheia Neuroenergetics is a biotechnology company developing first-in-class neuroenergetic gene therapies to treat patients with neurodegenerative diseases. Aletheia’s gene therapies are designed to address the fundamental impaired bioenergetics (manifest as decreased ATP bioavailability associated with mitochondrial dysfunction) that has emerged as a common denominator across the entire clinical spectrum of neurodegenerative disease.
For more information, please visit www.aletheianeuro.com and/or contact info@altheianeuro.com